H. Tsubery, M. Mironchik, M. Fridkin
Sep 10, 2004
Citations
0
Influential Citations
74
Citations
Quality indicators
Journal
Journal of Biological Chemistry
Abstract
Polyethylene glycol (PEG)-conjugated therapeutic peptides/proteins have been shown to exhibit clinical properties superior to those of their corresponding unmodified parent molecules. However, the desirable pharmacological features gained by protein PEGylation become irrelevant if conjugates are inactivated or cannot reach their target tissues. Here we describe the design and synthesis of MAL-FMS-OSU. This bifunctional agent enables PEG chains to be linked to peptides and proteins through a slowly hydrolysable chemical bond. PEG-FMS-peptide/protein conjugates thus formed undergo spontaneous hydrolysis at a slow rate upon incubation at pH 8.5, 37 °C with a t½ value of 8–14 ± 2 h, generating the unmodified parent molecule. The validity of this approach was studied with exendin-4 and human growth hormone. A single subcutaneous administration of PEG40,000-FMS-exendin-4 facilitated a prolonged and stable reduction in glucose levels in mice (t½ = 30 ± 2 h) and exceeded the effect obtained by the same dose of the native hormone by 7–8 times.